CEL-SCI: Food For Thought Before The Big Day [Seeking Alpha]
Cel-Sci Corporation (CVM)
NASDAQ:AMEX Investor Relations:
cel-sci.com/investor_relations.html
Company Research
Source: Seeking Alpha
Summary CEL-SCI is extremely likely to witness clinical trial success with its only product, Multikine. More than 350,000 patients die each year due to HSNCC. The drug has a total addressable market of over $2.0 billion in the U.S. alone. Top line data are anticipated by the end of April. CEL-SCI does not have to raise further cash to fund development efforts. Company Thesis Over the years, CEL-SCI Corp. ( CVM After carefully evaluating all relevant scientific evidence, investor presentations, and arguments from both sides, the author estimates CVM has an 85% chance of witnessing trial success in Multikine and will likely ten-bag if so. On the other hand, there is a 15% probability that the company may fail its investigation and see shares go to zero. The author believes the risks to be worth taking due to a high expected value, and presents below as to why this is the case. The Bear Case When more complete studies were available (regarding IL-2), complete responses to this regimen in
Show less
Read more
Impact Snapshot
Event Time:
CVM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CVM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CVM alerts
High impacting Cel-Sci Corporation news events
Weekly update
A roundup of the hottest topics
CVM
News
- CEL-SCI Appoints Mario Gobbo to Its Board of Directors [Yahoo! Finance]Yahoo! Finance
- CEL-SCI Appoints Mario Gobbo to Its Board of DirectorsBusiness Wire
- CEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology [Yahoo! Finance]Yahoo! Finance
- CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in ImmunologyBusiness Wire
- CEL-SCI Co. (NYSE: CVM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
CVM
Sec Filings
- 4/23/24 - Form 3
- 4/23/24 - Form 4
- 4/23/24 - Form 4
- CVM's page on the SEC website